Edgewise Therapeutics Inc Cash Flow Conversion Efficiency
Edgewise Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Edgewise Therapeutics Inc (EWTX) has a cash flow conversion efficiency ratio of -0.086x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-42.54 Million) by net assets ($493.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Edgewise Therapeutics Inc (2019–2025)
Cash flow conversion efficiency of Edgewise Therapeutics Inc from 2019 to 2025. This chart illustrates how Edgewise Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Edgewise Therapeutics Inc for real-time trading data and today's change.
Edgewise Therapeutics Inc Cash Flow Conversion Ratio Explained
Edgewise Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Edgewise Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Edgewise Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Edgewise Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Doximity Inc
NYSE:DOCS
|
0.115x |
|
EREGLI DEM CEL FABR DL1
F:EDVA
|
0.063x |
|
Shanghai Xinmei Real Estate Co Ltd Class A
SHG:600732
|
-0.011x |
|
Monday.Com Ltd
NASDAQ:MNDY
|
0.096x |
|
Liechtensteinische Landesbank Aktiengesellschaft
STU:LLS1
|
-0.060x |
|
Banijay Group NV
AS:BNJ
|
0.186x |
|
ENAGAS A.A. ADR1/2/EO150
F:EG40
|
0.014x |
|
Orla Mining Ltd
TO:OLA
|
0.139x |
Annual Cash Flow Conversion Efficiency for Edgewise Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Edgewise Therapeutics Inc from 2019 to 2025. Review Edgewise Therapeutics Inc (EWTX) flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $522.26 Million | $-143.82 Million | -0.275x | -15.99% |
| 2024-12-31 | $459.22 Million | $-109.03 Million | -0.237x | +17.67% |
| 2023-12-31 | $318.83 Million | $-91.95 Million | -0.288x | -89.97% |
| 2022-12-31 | $346.72 Million | $-52.63 Million | -0.152x | -24.31% |
| 2021-12-31 | $274.38 Million | $-33.51 Million | -0.122x | -127.89% |
| 2020-12-31 | $-33.42 Million | $-14.63 Million | 0.438x | -19.53% |
| 2019-12-31 | $-16.85 Million | $-9.17 Million | 0.544x | -- |
About Edgewise Therapeutics Inc
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company… Read more